31.06
Alkermes Plc (ALKS) 最新ニュース
Is Alkermes plc (8AK) stock cheap vs fundamentalsWeekly Trading Summary & AI Optimized Trade Strategies - newser.com
Is Alkermes plc reversing from oversold territoryJuly 2025 Drop Watch & Accurate Buy Signal Alerts - newser.com
Will Alkermes plc (8AK) stock hit Wall Street targetsVolume Spike & Comprehensive Market Scan Insights - newser.com
Technical analysis overview for Alkermes plc stockMarket Weekly Review & Fast Exit/Entry Strategy Plans - newser.com
Alkermes Plc Experiences Evaluation Revision Amidst Mixed Market Signals and Performance Trends - Markets Mojo
Alkermes sued over alleged scheme to block generic Vivitrol - Reuters
Is Alkermes plc a good long term investmentMACD Trading Signals & Investor Community Interactions - earlytimes.in
Will Alkermes plc (8AK) stock benefit from Fed rate cuts2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Can Alkermes plc stock deliver strong Q4 earningsPortfolio Growth Summary & Fast Gaining Stock Reports - newser.com
How cyclical is Alkermes plc (8AK) stock compared to rivals2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - newser.com
What candlestick patterns are forming on Alkermes plcJuly 2025 Patterns & Fast Gain Stock Trading Tips - newser.com
Is Alkermes plc (8AK) stock at risk of policy regulationRisk Management & Weekly Chart Analysis and Trade Guides - newser.com
Alkermes Plc Hits Day High with Strong 10.58% Intraday Surge - Markets Mojo
Alkermes (ALKS) Added to Wells Fargo's Tactical Ideas List - GuruFocus
What analysts say about Alkermes plc 8AK stockPrice-to-Earnings Ratio Insights & Budget Friendly Capital Growth - earlytimes.in
What drives Alkermes plc stock priceMarket Breadth Indicators & Explosive Profit Trading - earlytimes.in
Alkermes : Corporate Responsability Report - MarketScreener
Alkermes plc (ALKS) Stock Analysis: Exploring a 49.54% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
U.S. Buprenorphine Market Set for Dynamic Growth with Key - openPR.com
How Investors May Respond To Alkermes (ALKS) Phase 2 Alixorexton Narcolepsy Trial Outperformance - Sahm
Alkermes upgraded at RBC Capital Markets ahead of key catalyst - MSN
Is Alkermes' (ALKS) Narcolepsy Drug Breakthrough Shifting Its Investment Narrative? - Yahoo Finance
Alkermes Plc Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says - MarketScreener
Alkermes stock upgraded at RBC Capital Markets (ALKS:NASDAQ) - Seeking Alpha
Alkermes (NASDAQ:ALKS) Shares Gap Up After Analyst Upgrade - MarketBeat
Alkermes (NASDAQ:ALKS) Upgraded by Royal Bank Of Canada to "Outperform" Rating - MarketBeat
RBC Capital Upgrades ALKS: Price Target Raised to $44 | ALKS Sto - GuruFocus
RBC Capital Upgrades Alkermes (ALKS) - Nasdaq
RBC Capital Upgrades Alkermes to Outperform From Sector Perform, Adjusts PT to $44 From $42 - MarketScreener
Assenagon Asset Management S.A. Has $2.40 Million Position in Alkermes plc $ALKS - MarketBeat
Nanotechnology Drug Delivery Market Booming Rapidly - openPR.com
Oliver Luxxe Assets LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat
大文字化:
|
ボリューム (24 時間):